153 related articles for article (PubMed ID: 37747491)
1.
Giraud JS; Bièche I; Pasmant É; Tlemsani C
Expert Opin Investig Drugs; 2023; 32(10):941-957. PubMed ID: 37747491
[TBL] [Abstract][Full Text] [Related]
2. Akt- or MEK-mediated mTOR inhibition suppresses Nf1 optic glioma growth.
Kaul A; Toonen JA; Cimino PJ; Gianino SM; Gutmann DH
Neuro Oncol; 2015 Jun; 17(6):843-53. PubMed ID: 25534823
[TBL] [Abstract][Full Text] [Related]
3. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
4. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors.
Dasgupta B; Yi Y; Chen DY; Weber JD; Gutmann DH
Cancer Res; 2005 Apr; 65(7):2755-60. PubMed ID: 15805275
[TBL] [Abstract][Full Text] [Related]
5. Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.
Kobayashi D; Hirayama M; Komohara Y; Mizuguchi S; Wilson Morifuji M; Ihn H; Takeya M; Kuramochi A; Araki N
J Biol Chem; 2014 Sep; 289(38):26314-26326. PubMed ID: 25092287
[TBL] [Abstract][Full Text] [Related]
6. Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma.
Lau N; Feldkamp MM; Roncari L; Loehr AH; Shannon P; Gutmann DH; Guha A
J Neuropathol Exp Neurol; 2000 Sep; 59(9):759-67. PubMed ID: 11005256
[TBL] [Abstract][Full Text] [Related]
7. Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells.
Varin J; Poulain L; Hivelin M; Nusbaum P; Hubas A; Laurendeau I; Lantieri L; Wolkenstein P; Vidaud M; Pasmant E; Chapuis N; Parfait B
Oncotarget; 2016 Jun; 7(24):35753-35767. PubMed ID: 26840085
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors.
Endo M; Yamamoto H; Setsu N; Kohashi K; Takahashi Y; Ishii T; Iida K; Matsumoto Y; Hakozaki M; Aoki M; Iwasaki H; Dobashi Y; Nishiyama K; Iwamoto Y; Oda Y
Clin Cancer Res; 2013 Jan; 19(2):450-61. PubMed ID: 23209032
[TBL] [Abstract][Full Text] [Related]
9. MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.
Brundage ME; Tandon P; Eaves DW; Williams JP; Miller SJ; Hennigan RH; Jegga A; Cripe TP; Ratner N
Oncogene; 2014 Dec; 33(49):5626-36. PubMed ID: 24509877
[TBL] [Abstract][Full Text] [Related]
10. The promise of signal transduction in genetically driven sarcomas of the nerve.
Kim A; Pratilas CA
Exp Neurol; 2018 Jan; 299(Pt B):317-325. PubMed ID: 28859862
[TBL] [Abstract][Full Text] [Related]
11. The NF1 tumor suppressor critically regulates TSC2 and mTOR.
Johannessen CM; Reczek EE; James MF; Brems H; Legius E; Cichowski K
Proc Natl Acad Sci U S A; 2005 Jun; 102(24):8573-8. PubMed ID: 15937108
[TBL] [Abstract][Full Text] [Related]
12. NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.
House RRJ; Tovar EA; Redlon LN; Essenburg CJ; Dischinger PS; Ellis AE; Beddows I; Sheldon RD; Lien EC; Graveel CR; Steensma MR
Mol Metab; 2024 Feb; 80():101876. PubMed ID: 38216123
[TBL] [Abstract][Full Text] [Related]
13. Kinome Profiling of NF1-Related MPNSTs in Response to Kinase Inhibition and Doxorubicin Reveals Therapeutic Vulnerabilities.
Grit JL; Pridgeon MG; Essenburg CJ; Wolfrum E; Madaj ZB; Turner L; Wulfkuhle J; Petricoin EF; Graveel CR; Steensma MR
Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32245042
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
[TBL] [Abstract][Full Text] [Related]
15. Emerging therapeutic targets for neurofibromatosis type 1.
Walker JA; Upadhyaya M
Expert Opin Ther Targets; 2018 May; 22(5):419-437. PubMed ID: 29667529
[TBL] [Abstract][Full Text] [Related]
16. Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions.
Yang FC; Chen S; Robling AG; Yu X; Nebesio TD; Yan J; Morgan T; Li X; Yuan J; Hock J; Ingram DA; Clapp DW
J Clin Invest; 2006 Nov; 116(11):2880-91. PubMed ID: 17053831
[TBL] [Abstract][Full Text] [Related]
17. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft.
Bhola P; Banerjee S; Mukherjee J; Balasubramanium A; Arun V; Karim Z; Burrell K; Croul S; Gutmann DH; Guha A
Int J Cancer; 2010 Jan; 126(2):563-71. PubMed ID: 19634141
[TBL] [Abstract][Full Text] [Related]
18. Cotargeting MNK and MEK kinases induces the regression of NF1-mutant cancers.
Lock R; Ingraham R; Maertens O; Miller AL; Weledji N; Legius E; Konicek BM; Yan SC; Graff JR; Cichowski K
J Clin Invest; 2016 Jun; 126(6):2181-90. PubMed ID: 27159396
[TBL] [Abstract][Full Text] [Related]
19. Ras-Mek-Erk signaling regulates Nf1 heterozygous neointima formation.
Stansfield BK; Bessler WK; Mali R; Mund JA; Downing BD; Kapur R; Ingram DA
Am J Pathol; 2014 Jan; 184(1):79-85. PubMed ID: 24211110
[TBL] [Abstract][Full Text] [Related]
20. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
Wang J; Pollard K; Calizo A; Pratilas CA
Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
